Bezuclastinib
cogent biosciences, inc.
['apex']
#bezuclastinib treatment leads to reductions in serum tryptase levels and bone marrow #mastcells in patients with advanced #systemicmastocytosis, according to results from a phase 2 #clinicaltrial named apex presented at the 2022 congress. 
Trusted knowledge base of practical information and resources focused on treating and diagnosing rare disease.